AXIOS highlights the FDA’s announcement to postpone its advisory committee meeting for HRA Pharma’s application for an over-the-counter birth control pill.
FDA postpones meeting to review over-the-counter birth control pills
Previous
Previous
U.S. FDA delays panel meeting on Perrigo's OTC birth control pill
Next
Next